Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Distinct in vivo roles of secreted APP ectodomain variants APPsα and APPsβ in regulation of spine density, synaptic plasticity, and cognition.

Richter MC, Ludewig S, Winschel A, Abel T, Bold C, Salzburger LR, Klein S, Han K, Weyer SW, Fritz AK, Laube B, Wolfer DP, Buchholz CJ, Korte M, Müller UC.

EMBO J. 2018 Apr 16. pii: e98335. doi: 10.15252/embj.201798335. [Epub ahead of print]

PMID:
29661886
2.

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ, Muik A.

Oncotarget. 2018 Jan 12;9(16):12971-12981. doi: 10.18632/oncotarget.24191. eCollection 2018 Feb 27.

3.

Displaying Tetra-Membrane Spanning Claudins on Enveloped Virus-Like Particles for Cancer Immunotherapy.

Schneider IC, Hartmann J, Braun G, Stitz J, Klamp T, Bihi M, Sahin U, Buchholz CJ.

Biotechnol J. 2018 Mar;13(3):e1700345. doi: 10.1002/biot.201700345. Epub 2017 Nov 23.

PMID:
29131519
4.

Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138.

PMID:
28870120
5.

Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transfer.

Muik A, Reul J, Friedel T, Muth A, Hartmann KP, Schneider IC, Münch RC, Buchholz CJ.

Biomaterials. 2017 Nov;144:84-94. doi: 10.1016/j.biomaterials.2017.07.032. Epub 2017 Jul 25.

PMID:
28825979
6.

Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts.

Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ.

EMBO Mol Med. 2017 Sep;9(9):1183-1197. doi: 10.15252/emmm.201607485. Review.

7.

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.

Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ.

Front Oncol. 2017 Jun 26;7:127. doi: 10.3389/fonc.2017.00127. eCollection 2017.

8.

A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.

Wagner J, Pfannenstiel V, Waldmann A, Bergs JWJ, Brill B, Huenecke S, Klingebiel T, Rödel F, Buchholz CJ, Wels WS, Bader P, Ullrich E.

Front Immunol. 2017 Jun 12;8:676. doi: 10.3389/fimmu.2017.00676. eCollection 2017.

9.

Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells.

Wang X, Herzog RW, Byrne BJ, Kumar SRP, Zhou Q, Buchholz CJ, Biswas M.

Mol Ther Methods Clin Dev. 2017 Mar 29;5:76-82. doi: 10.1016/j.omtm.2017.03.005. eCollection 2017 Jun 16.

10.

Endothelial transcription factor KLF2 negatively regulates liver regeneration via induction of activin A.

Manavski Y, Abel T, Hu J, Kleinlützum D, Buchholz CJ, Belz C, Augustin HG, Boon RA, Dimmeler S.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3993-3998. doi: 10.1073/pnas.1613392114. Epub 2017 Mar 27.

11.

Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment.

Bender RR, Muth A, Schneider IC, Friedel T, Hartmann J, Plückthun A, Maisner A, Buchholz CJ.

PLoS Pathog. 2016 Jun 9;12(6):e1005641. doi: 10.1371/journal.ppat.1005641. eCollection 2016 Jun.

12.

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.

Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS.

Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11.

13.

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.

Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD.

Mol Ther Oncolytics. 2016 Feb 24;3:16003. doi: 10.1038/mto.2016.3. eCollection 2016.

14.

CD30 Receptor-Targeted Lentiviral Vectors for Human Induced Pluripotent Stem Cell-Specific Gene Modification.

Friedel T, Jung-Klawitter S, Sebe A, Schenk F, Modlich U, Ivics Z, Schumann GG, Buchholz CJ, Schneider IC.

Stem Cells Dev. 2016 May 1;25(9):729-39. doi: 10.1089/scd.2015.0386. Epub 2016 Apr 11.

PMID:
26956718
15.

Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer's disease mouse model.

Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer JP, Brod F, Audrain M, Bemelmans AP, Buchholz CJ, Korte M, Cartier N, Müller UC.

Acta Neuropathol. 2016 Feb;131(2):247-266. doi: 10.1007/s00401-015-1498-9. Epub 2015 Nov 4.

PMID:
26538149
16.

Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery.

Buchholz CJ, Friedel T, Büning H.

Trends Biotechnol. 2015 Dec;33(12):777-790. doi: 10.1016/j.tibtech.2015.09.008. Epub 2015 Oct 20. Review.

PMID:
26497425
17.

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Zhou Q, Uhlig KM, Muth A, Kimpel J, Lévy C, Münch RC, Seifried J, Pfeiffer A, Trkola A, Coulibaly C, von Laer D, Wels WS, Hartwig UF, Verhoeyen E, Buchholz CJ.

J Immunol. 2015 Sep 1;195(5):2493-501. doi: 10.4049/jimmunol.1500956. Epub 2015 Jul 31.

18.

In vitro incorporation of a cell-binding protein to a lentiviral vector using an engineered split intein enables targeted delivery of genetic cargo.

Chamoun-Emanuelli AM, Wright G, Roger S 3rd, Münch RC, Buchholz CJ, Chen Z.

Biotechnol Bioeng. 2015 Dec;112(12):2611-7. doi: 10.1002/bit.25685. Epub 2015 Aug 12.

PMID:
26108964
19.

Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.

Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD.

J Virol. 2015 Sep;89(17):9044-60. doi: 10.1128/JVI.00844-15. Epub 2015 Jun 17.

20.

Mapping the BH3 Binding Interface of Bcl-xL, Bcl-2, and Mcl-1 Using Split-Luciferase Reassembly.

Campbell ST, Carlson KJ, Buchholz CJ, Helmers MR, Ghosh I.

Biochemistry. 2015 Apr 28;54(16):2632-43. doi: 10.1021/bi501505y. Epub 2015 Apr 13.

PMID:
25844633
21.

Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv.

Friedel T, Hanisch LJ, Muth A, Honegger A, Abken H, Plückthun A, Buchholz CJ, Schneider IC.

Protein Eng Des Sel. 2015 Apr;28(4):93-106. doi: 10.1093/protein/gzv005. Epub 2015 Feb 25.

PMID:
25715658
22.

Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.

Münch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, Trkola A, Plückthun A, Büning H, Buchholz CJ.

Nat Commun. 2015 Feb 10;6:6246. doi: 10.1038/ncomms7246.

PMID:
25665714
23.

Selective lentiviral gene delivery to CD133-expressing human glioblastoma stem cells.

Bayin NS, Modrek AS, Dietrich A, Lebowitz J, Abel T, Song HR, Schober M, Zagzag D, Buchholz CJ, Chao MV, Placantonakis DG.

PLoS One. 2014 Dec 26;9(12):e116114. doi: 10.1371/journal.pone.0116114. eCollection 2014.

24.

CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells.

Kays SK, Kaufmann KB, Abel T, Brendel C, Bonig H, Grez M, Buchholz CJ, Kneissl S.

Stem Cells Dev. 2015 Mar 15;24(6):714-23. doi: 10.1089/scd.2014.0455. Epub 2015 Jan 20.

25.

CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells.

Brendel C, Goebel B, Daniela A, Brugman M, Kneissl S, Schwäble J, Kaufmann KB, Müller-Kuller U, Kunkel H, Chen-Wichmann L, Abel T, Serve H, Bystrykh L, Buchholz CJ, Grez M.

Mol Ther. 2015 Jan;23(1):63-70. doi: 10.1038/mt.2014.173. Epub 2014 Sep 5. Erratum in: Mol Ther. 2015 Apr;23(4):790.

26.

Holo-APP and G-protein-mediated signaling are required for sAPPα-induced activation of the Akt survival pathway.

Milosch N, Tanriöver G, Kundu A, Rami A, François JC, Baumkötter F, Weyer SW, Samanta A, Jäschke A, Brod F, Buchholz CJ, Kins S, Behl C, Müller UC, Kögel D.

Cell Death Dis. 2014 Aug 28;5:e1391. doi: 10.1038/cddis.2014.352.

27.

Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo.

Ciré S, Da Rocha S, Yao R, Fisson S, Buchholz CJ, Collins MK, Galy A.

PLoS One. 2014 Jul 24;9(7):e101644. doi: 10.1371/journal.pone.0101644. eCollection 2014.

28.

A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains.

Heidmeier S, Hanauer JR, Friedrich K, Prüfer S, Schneider IC, Buchholz CJ, Cichutek K, Mühlebach MD.

Virus Res. 2014 Feb 13;180:43-8. doi: 10.1016/j.virusres.2013.12.016. Epub 2013 Dec 22.

PMID:
24368277
29.

CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.

Kneissl S, Zhou Q, Schwenkert M, Cosset FL, Verhoeyen E, Buchholz CJ.

PLoS One. 2013 Nov 11;8(11):e79047. doi: 10.1371/journal.pone.0079047. eCollection 2013.

30.

Specific gene delivery to liver sinusoidal and artery endothelial cells.

Abel T, El Filali E, Waern J, Schneider IC, Yuan Q, Münch RC, Hick M, Warnecke G, Madrahimov N, Kontermann RE, Schüttrumpf J, Müller UC, Seppen J, Ott M, Buchholz CJ.

Blood. 2013 Sep 19;122(12):2030-8. doi: 10.1182/blood-2012-11-468579. Epub 2013 Jul 24.

31.

Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques.

Völker I, Bach P, Coulibaly C, Plesker R, Abel T, Seifried J, Heidmeier S, Mühlebach MD, Lauer UM, Buchholz CJ.

Hum Gene Ther Clin Dev. 2013 Mar;24(1):11-22. doi: 10.1089/humc.2012.242. Epub 2013 Apr 3.

PMID:
23692379
32.

The receptor attachment function of measles virus hemagglutinin can be replaced with an autonomous protein that binds Her2/neu while maintaining its fusion-helper function.

Rasbach A, Abel T, Münch RC, Boller K, Schneider-Schaulies J, Buchholz CJ.

J Virol. 2013 Jun;87(11):6246-56. doi: 10.1128/JVI.03298-12. Epub 2013 Mar 27.

33.
34.

DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Friedrich K, Hanauer JR, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD.

Mol Ther. 2013 Apr;21(4):849-59. doi: 10.1038/mt.2013.16. Epub 2013 Feb 5.

35.

Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ.

Cancer Res. 2013 Jan 15;73(2):865-74. doi: 10.1158/0008-5472.CAN-12-2221. Epub 2013 Jan 4.

36.

Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.

Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, Buchholz CJ.

PLoS One. 2012;7(10):e46667. doi: 10.1371/journal.pone.0046667. Epub 2012 Oct 10.

37.

Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.

Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H, Buchholz CJ.

Mol Ther. 2013 Jan;21(1):109-18. doi: 10.1038/mt.2012.186. Epub 2012 Sep 11.

38.

T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.

Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schönfeld K, Schambach A, Wels WS, Kneissl S, Uckert W, Buchholz CJ.

Blood. 2012 Nov 22;120(22):4334-42. doi: 10.1182/blood-2012-02-412973. Epub 2012 Aug 16.

39.

The European hospital exemption clause-new option for gene therapy?

Buchholz CJ, Sanzenbacher R, Schüle S.

Hum Gene Ther. 2012 Jan;23(1):7-12. doi: 10.1089/hum.2011.2529.

PMID:
22247961
40.

Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.

Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfeld C.

Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.

PMID:
22218301
41.

Escape from R-peptide deletion in a γ-retrovirus.

Schneider IC, Eckhardt M, Brynza J, Collins MK, Cichutek K, Buchholz CJ.

Virology. 2011 Sep 30;418(2):85-92. doi: 10.1016/j.virol.2011.07.011. Epub 2011 Aug 10.

42.

RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.

Schaser T, Wrede C, Duerner L, Sliva K, Cichutek K, Schnierle B, Buchholz CJ.

Gene Ther. 2011 Oct;18(10):953-60. doi: 10.1038/gt.2011.48. Epub 2011 Apr 7.

PMID:
21472010
43.

Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM.

Zhou Q, Schneider IC, Gallet M, Kneissl S, Buchholz CJ.

Virology. 2011 May 10;413(2):149-52. doi: 10.1016/j.virol.2011.02.010. Epub 2011 Apr 5.

44.

Lentiviral vectors targeted to MHC II are effective in immunization.

Ageichik A, Buchholz CJ, Collins MK.

Hum Gene Ther. 2011 Oct;22(10):1249-54. doi: 10.1089/hum.2010.184. Epub 2011 Mar 23.

PMID:
21247346
45.

DARPins: an efficient targeting domain for lentiviral vectors.

Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ.

Mol Ther. 2011 Apr;19(4):686-93. doi: 10.1038/mt.2010.298. Epub 2011 Jan 11.

46.

Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.

Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, Schneider IC, Münch RC, Petznek H, Kontermann RE, Koehl U, Johnston IC, Keinänen K, Müller UC, Hohenadl C, Monyer H, Cichutek K, Buchholz CJ.

Nat Methods. 2010 Nov;7(11):929-35. doi: 10.1038/nmeth.1514. Epub 2010 Oct 10.

PMID:
20935652
47.

Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.

Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KM, Cattaneo R, Bitzer M, Lauer UM, Cichutek K, Buchholz CJ.

Cancer Res. 2010 Oct 1;70(19):7620-9. doi: 10.1158/0008-5472.CAN-09-4650. Epub 2010 Sep 21.

48.

Environmental risk assessment for medicinal products containing genetically modified organisms.

Anliker B, Longhurst S, Buchholz CJ.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Jan;53(1):52-7. doi: 10.1007/s00103-009-0986-2.

PMID:
19940966
49.

Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice.

Bach P, Tschäpe JA, Kopietz F, Braun G, Baade JK, Wiederhold KH, Staufenbiel M, Prinz M, Deller T, Kalinke U, Buchholz CJ, Müller UC.

J Immunol. 2009 Jun 15;182(12):7613-24. doi: 10.4049/jimmunol.0803366.

50.

Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer?

Buchholz CJ, Mühlebach MD, Cichutek K.

Trends Biotechnol. 2009 May;27(5):259-65. doi: 10.1016/j.tibtech.2009.02.002. Epub 2009 Mar 25. Review.

PMID:
19327858

Supplemental Content

Loading ...
Support Center